In December 2023, the R-ONE® system received NMPA approval (Registration No. 国械注准20233011579), becoming the first commercialized coronary vascular intervention surgical robot in China to complete multi-center clinical trials. In July 2023, the company ACHieved china's first 5G remote robot-assisted PCI surgery performed by 301 Hospital across 2,800 kilometers. In 2025, the company was recognized as a National Technology-based Small and Medium-sized Enterprise.
Company Overview (Updated April 2026)
Zhimai (Shanghai) Robot Co., Ltd. (Chinese: 知脉（上海）机器人有限公司) is a medical device company headquartered in Shanghai, China (China (Shanghai) Pilot Free Trade Zone). Founded on March 19, 2021, the company is a joint venture established with a registered capital of €10 million between MicroPort Medical Robot (Group) Co., Ltd. (holding 51%) and Robocath S.A.S of France (holding 49%).
Mission: To introduce, localize, and commercialize the R-ONE® vascular intervention surgical robot system in China, while developing localized production and assembly capabilities and advancing remote interventional surgery and artificial intelligence technologies.
Corporate History and Development (2021-2026)
Establishment and Founding (2021)
- March 19, 2021: Company established as a Sino-French joint venture in Shanghai Free Trade Zone
- Shareholders: MicroPort Medical Robot (Group) Co., Ltd. (51%) and Robocath S.A.S (49%)
- Registered Capital: €10 million
- Strategic Objective: Introduce R-ONE® system to China and achieve localization in production, assembly, and R&D
Clinical and Regulatory Milestones (2023)
- July 2023: China's first 5G remote robot-assisted PCI surgery completed by 301 Hospital using R-ONE®, spanning 2,800 kilometers
- December 2023: R-ONE® received NMPA Class III medical device registration (国械注准20233011579), becoming the first commercialized coronary vascular intervention surgical robot in China to complete multi-center clinical trials
Commercialization and Recognition (2024-2025)
- 2024 onwards: R-ONE® system installed in multiple Class III Grade A hospitals across China, with commercialization accelerating in collaboration with MicroPort's coronary business
- 2025: Recognized as a National Technology-based Small and Medium-sized Enterprise (科技型中小企业)
Core Product: R-ONE® Vascular Intervention Surgical Robot System
Technology Overview
The R-ONE® is a robot-assisted system for percutaneous coronary intervention (PCI) procedures based on master-slave control technology:
- Master-Slave Control: Physician operates from a radiation-protected console while robotic arm executes precise movements
- Key Functions: 0–360° continuous rotation and translation, sub-millimeter stepping, one-button lock/unlock
- Clinical Application: Assists physicians in delivering and manipulating coronary guidewires, Rapid-exchange balloon catheters, and stent systems during PCI
- Indications: Percutaneous coronary intervention (PCI); not indicated for emergency cases, left main lesions, chronic total occlusions (CTO), or bifurcation lesions
Core Technical Features
- Bionic Dual-Hand搓捻 Technology: Simulates physician hand movements for guidewire manipulation
- Radiation-Protected Ergonomic Console: Physician operates seated without lead apron, reducing radiation exposure and physical fatigue
- DisposAble Full-Coverage Sterile Consumables: Quick-install/quick-remove sterile drape design for efficient procedure setup
- 5G Remote Capability: Supports ultra-remote surgery via 5G network with real-time control
Localization Strategy
- Local Production: Established production line in Shanghai Free Trade Zone for domestic assembly and manufacturing
- After-Sales Support: Built localized service network for maintenance, training, and clinical support
- R&D Expansion: Collaborating on development of robotic systems for other vascular interventional procedures and AI-assisted surgical technologies
Market Position and Competitive Landscape
Market Status:
- First NMPA-approved commercialized coronary vascular intervention robot in China
- Competing with imported systems from Siemens Healthineers and domestic players such as Beijing We Medical Technology Co., Ltd.
- China's PCI surgical robot market is in early-stage development with significant growth potential
Company Information
Corporate Details
Legal Name: Zhimai (Shanghai) Robot Co., Ltd. (知脉（上海）机器人有限公司)
Founded: March 19, 2021
Registered Address: Room 1817, 18th Floor (Actual 16th Floor), Building 1, No. 1601 Zhangdong Road, China (Shanghai) Pilot Free Trade Zone
Phone: 021-38954600
Email: medbot@microport.com
Status: Joint venture (private)
Industry: Medical Devices - Surgical Robotics / Vascular Intervention / Cardiology
Registered Capital: €10 million
Shareholder Structure
- MicroPort Medical Robot (Group) Co., Ltd.: 51% (Shanghai-listed: 02252.HK)
- Robocath S.A.S (France): 49% (Founded by Dr. Lucien Goffart; headquartered in Rouen, France)
Key Products
- R-ONE® Vascular Intervention Surgical Robot System (NMPA Registration: 国械注准20233011579)
- Disposable sterile consumables and accessories for robotic PCI procedures
Keywords: Zhimai Shanghai Robot, R-ONE, vascular intervention robot, PCI, robot-assisted surgery, MicroPort, Robocath, 5G remote surgery, NMPA, coronary intervention, Shanghai Free Trade Zone, 2021 founded, 知脉机器人
